Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Sarcoma and Rare Cancers 2023 | CCS: present treatment options and current unmet needs

Antonia Digklia, MD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, discusses her recent review on clear-cell sarcoma (CCS), which utilized case reports to study the use of molecular targeted therapies in patients. Dr Digklia highlights that targeted therapy is essential, due to the heterogenous nature of CCS, which she emphasizes through the example of the PDGFRA D842V mutation, a molecular target for avapritinib. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.